Neuronetics (NASDAQ:STIM) Azioni

Neuronetics

Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.

Penny Stocks

Markets

CNTM

STIM

Scopri le 3 azioni a basso prezzo che stanno attirando l&#39;attenzione degli insider questa settimana e perché.

3 azioni a basso prezzo da tenere d&#39;occhio questa settimana

Long Ideas

News

Insider Trades

Pre-Market Outlook

Trading Ideas

BFLY

HYFM

Le recenti operazioni degli insider che puntano su queste quattro penny stock. Scopri quali azioni stanno attirando l&#39;attenzione e perché.

4 penny stock sotto la lente d&#39;ingrandimento degli insider

Neuronetics Inc

Stimcell Energetics Inc

STIMCELL ENERGETICS INC by Stimcell Energetics, Inc.

Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024
<ul>
<li>a $0.6 million reduction in the 2024 bonus accrual that the Company assumed in connection with its acquisition of Greenbrook, resulting in an increase in the Company's operating expenses from $25.8 million, as reported in the Initial Release, to $26.4 million under applicable purchasing accounting principles;</li>
<li>an increase in the net loss and net loss per share from $(12.2) million and $(0.33), respectively, as reported in the Initial Release, to $(12.7) million and $(0.34), respectively; and</li>
<li>a decrease in the adjusted EBITDA from $0.1 million, as reported in the Initial Release, to $(0.4) million.</li>
</ul>

Earnings

Neuronetics Reports Updated Q4 Results; Net Loss $(0.33)

Canaccord Genuity analyst William Plovanic maintains Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) with a Buy and raises the price target from $5 to $8.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Neuronetics, Raises Price Target to $8

Citizens Capital Markets analyst Daniel Stauder maintains Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) with a Market Outperform and raises the price target from $3 to $7.

Citizens Capital Markets Maintains Market Outperform on Neuronetics, Raises Price Target to $7

WIIM

Neuronetics shares are trading higher after Citizens JMP and Canaccord raised their respective price targets on the stock.

Business Outlook
For the first quarter of 2025, the Company expects total worldwide revenue between $28.0&nbsp;million and $30.0&nbsp;million.
For the full year 2025, the Company expects total worldwide revenue to be between $145.0&nbsp;million and $155.0&nbsp;million.
For the full year 2025, the Company expects gross margin to be approximately 55%.
For the full year 2025, the Company expects total operating expenses to be between $90.0&nbsp;million and $98.0&nbsp;million.

Guidance

Neuronetics Expects Q1 Revenue Of $28M-$30M Vs $21.02M Est, FY25 Revenue Of $145M-$155M Vs $93.55M Est

Earnings Beats

Earnings Misses

Neuronetics Q4 2024 GAAP EPS $(0.33) Misses $(0.17) Estimate, Sales $22.493M Beat $19.634M Estimate

<h3>Companies Reporting Before The Bell</h3>
• 908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) is likely to report quarterly loss at $0.37 per share on revenue of $16.18 million. 
• Plug Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) is projected to report quarterly loss at $0.23 per share on revenue of $262.65 million. 
• NexGen Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXE#NYSE">NXE</a>) is projected to report earnings for its fourth quarter. 
• EVgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is estimated to report quarterly loss at $0.09 per share on revenue of $69.00 million. 
• L.B. Foster (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSTR#NASDAQ">FSTR</a>) is estimated to report quarterly earnings at $0.22 per share on revenue of $131.48 million. 
• WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $25.59 million. 
• InfuSystems Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INFU#AMEX">INFU</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $34.40 million. 
• Amylyx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) is expected to report earnings for its fourth quarter. 
• Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) is projected to report quarterly loss at $0.24 per share on revenue of $18.98 million. 
• Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $26.94 million. 
• Olaplex Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $87.51 million. 
• Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) is expected to report quarterly earnings at $0.01 per share on revenue of $279.58 million. 
• Angel Oak Mortgage REIT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AOMR#NYSE">AOMR</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $9.99 million. 
• Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $63.06 million. 
• Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) is expected to report quarterly loss at $0.15 per share on revenue of $17.71 million. 
• Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) is projected to report quarterly earnings at $0.72 per share on revenue of $437.22 million. 
• Compugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEN#NASDAQ">CGEN</a>) is likely to report quarterly loss at $0.07 per share on revenue of $24.96 million. 
• Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) is expected to report quarterly earnings at $0.70 per share on revenue of $4.60 billion. 
• Genius Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GENI#NYSE">GENI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $175.71 million. 
• On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $593.34 million. 
• Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $91.89 million. 
• Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) is likely to report quarterly earnings at $2.42 per share on revenue of $13.69 billion. 
• Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) is likely to report quarterly earnings at $2.65 per share on revenue of $30.28 billion. 
• CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $118.97 million. 
• Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $290.88 million. 
• Modiv Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDV#NYSE">MDV</a>) is expected to report quarterly earnings at $0.27 per share on revenue of $11.86 million. 
• AutoZone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) is estimated to report quarterly earnings at $29.90 per share on revenue of $4.00 billion. 
<h3>Companies Reporting After The Bell</h3>
• Medallion Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFIN#NASDAQ">MFIN</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $53.66 million. 
• Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is projected to report quarterly loss at $0.49 per share on revenue of $230.13 million. 
• Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $41.00 million. 
• Cumberland (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) is projected to report earnings for its fourth quarter. 
• Baytex Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTE#NYSE">BTE</a>) is estimated to report quarterly earnings at $0.16 per share on revenue of $980.40 million. 
• Stellus Cap Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCM#NYSE">SCM</a>) is estimated to report quarterly earnings at $0.39 per share on revenue of $26.54 million. 
• ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $26.52 million. 
• Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) is expected to report quarterly earnings at $0.33 per share on revenue of $57.60 million. 
• Astronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATRO#NASDAQ">ATRO</a>) is likely to report quarterly earnings at $0.28 per share on revenue of $194.91 million. 
• Fuel Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTEK#NASDAQ">FTEK</a>) is expected to report quarterly loss at $0.03 per share on revenue of $5.63 million. 
• comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $91.66 million. 
• Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $8.78 million. 
• Mayville Engineering (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEC#NYSE">MEC</a>) is projected to report quarterly loss at $0.08 per share on revenue of $124.13 million. 
• NeuroPace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $21.11 million. 
• ATN International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNI#NASDAQ">ATNI</a>) is projected to report quarterly loss at $0.19 per share on revenue of $179.11 million. 
• Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) is projected to report quarterly loss at $0.16 per share on revenue of $49.37 million. 
• OrthoPediatrics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDS#NASDAQ">KIDS</a>) is projected to report quarterly loss at $0.26 per share on revenue of $52.70 million. 
• Ascent Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>) is expected to report earnings for its fourth quarter. 
• Ecopetrol (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EC#NYSE">EC</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $7.68 billion. 
• Horizon Tech Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRZN#NASDAQ">HRZN</a>) is projected to report quarterly earnings at $0.32 per share on revenue of $25.68 million. 
• Owlet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OWLT#NYSE">OWLT</a>) is expected to report quarterly loss at $0.48 per share on revenue of $16.92 million. 
• AeroVironment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVAV#NASDAQ">AVAV</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $214.00 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $5.95 billion. 
• Evolus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $77.23 million. 
• Eos Energy Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) is expected to report quarterly loss at $0.20 per share on revenue of $6.23 million. 
• CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) is expected to report quarterly loss at $0.31 per share on revenue of $58.79 million. 
• Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $13.22 billion. 
• ChargePoint Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHPT#NYSE">CHPT</a>) is likely to report quarterly loss at $0.07 per share on revenue of $100.97 million. 
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is estimated to report quarterly earnings at $0.18 per share on revenue of $120.31 million. 
• Crexendo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXDO#NASDAQ">CXDO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $15.64 million. 
• CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $1.03 billion. 
• Ooma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OOMA#NYSE">OOMA</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $64.70 million. 
• Custom Truck One Source (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTOS#NYSE">CTOS</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $539.81 million. 
• Cricut (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRCT#NASDAQ">CRCT</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $214.41 million. 
• Orion Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $272.70 million. 
• Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) is likely to report quarterly loss at $0.01 per share on revenue of $84.95 million. 
• Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) is estimated to report quarterly earnings at $0.41 per share on revenue of $278.60 million. 
• Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) is projected to report quarterly earnings at $0.91 per share on revenue of $223.23 million. 
• Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) is projected to report earnings for its fourth quarter. 
• Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) is likely to report quarterly earnings at $0.84 per share on revenue of $1.13 billion. 
• Nordstrom (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) is likely to report quarterly earnings at $0.90 per share on revenue of $4.33 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACNT

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AOMR

ATNI

ATRO

AVAV

CDXC

CGEN

CHPT

CPIX

CRCT

CRDO

CRWD

CTOS

CXDO

CYRX

EOLS

EOSE

ESPR

EVGO

FSTR

FTEK

GENI

GIFI

HGTY

HRZN

INFU

INGM

KIDS

MASS

MFIN

NPCE

Nuveen Arizona Dividend Advantage Municipal Funds 3

NYAX

OLPX

ONON

OOMA

OWLT

PLUG

PMTS

PSFE

RIGL

ROST

SCOR

SLND

SOPH

STEM

SWIM

TKNO

WEYS

YMAB

Earnings Scheduled For March 4, 2025

<h3>Gainers</h3>
<ul>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares rose 74.0% to $1.34 during Friday's pre-market session. The market value of their outstanding shares is at $43.8 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 73.54% to $2.69. The market value of their outstanding shares is at $4.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 31.55% to $0.21. The market value of their outstanding shares is at $1.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 23.48% to $71.94. The market value of their outstanding shares is at $13.4 billion. The company's, Q3 earnings came out yesterday. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock rose 13.18% to $3.52. The market value of their outstanding shares is at $61.7 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares moved upwards by 12.78% to $3.97. The market value of their outstanding shares is at $188.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares declined by 24.2% to $1.22 during Friday's pre-market session. The market value of their outstanding shares is at $58.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 17.3% to $5.45. The company's market cap stands at $296.5 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares decreased by 16.15% to $126.21. The market value of their outstanding shares is at $12.7 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) stock decreased by 14.9% to $3.03. The company's market cap stands at $168.6 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 13.57% to $9.94. The company's market cap stands at $30.2 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) shares fell 13.02% to $1.27. The market value of their outstanding shares is at $30.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALMS

CYTH

DOCS

GUTS

NBIX

NBTX

NVNO

RNXT

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

Neuronetics shares are trading lower after the company announced the pricing of a $18 million public offering of 8 million shares at $2.25 per share.

The Company currently intends to use the net proceeds of this offering for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures.

Offerings

Neuronetics Prices Public Offering Of 8M Shares Of Common Stock At $2.25 Per Share, Resulting In Gross Proceeds Of $18M

<h3>Gainers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 67.7% to $0.27 during Friday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock moved upwards by 24.42% to $72.49. The company's market cap stands at $13.5 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 16.49% to $7.77. The market value of their outstanding shares is at $86.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 15.25% to $0.68. The company's market cap stands at $2.5 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 14.37% to $1.83. The company's market cap stands at $64.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock moved upwards by 8.62% to $0.65. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) stock decreased by 24.2% to $1.22 during Friday's pre-market session. The company's market cap stands at $58.6 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 21.92% to $2.78. The company's market cap stands at $154.7 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) stock fell 16.55% to $5.5. The market value of their outstanding shares is at $299.2 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock fell 13.57% to $9.94. The market value of their outstanding shares is at $30.2 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 12.26% to $4.08. The market value of their outstanding shares is at $4.9 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock declined by 11.65% to $132.98. The market value of their outstanding shares is at $13.4 billion. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBLG

HSDT

LIPO

NTRB

TNFA

Neuronetics shares are trading lower after the company announced a public offering, size not yet disclosed.

Neuronetics Announces Underwritten Public Offering; Size Not Disclosed

Rumors

Politics

General

Watching Neuronetics; Shares See Volume After U.S. Senate Finance Committee Votes 14-13 To Advance Kennedy Nomination Favorably

The first provides compelling evidence that transcranial magnetic stimulation (TMS) induces universal improvement in depressive symptoms. The second paper demonstrates the superior sensitivity of one widely used depression assessment (the Patient Health Questionnaire-9, or PHQ-9) over another (the Quick Inventory of Depressive Symptomatology: Self-Report, or QIDS-SR) for measuring TMS outcomes.

Biotech

Neuronetics Publishes Two-Peer-Reviewed Publications In Transcranial Magnetic Stimulation journal

Neurtonetics shares are trading higher after the company announced preliminary Q4 and FY24 revenue results.

<ul>
<li>Preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectively</li>
<li>Closed acquisition of Greenbrook TMS effective as of December 9, 2024</li>
<li>Expects full year 2025 pro forma year-over-year revenue growth of 12% - 19%</li>
<li>Expects to realize over $22 million in annualized cost synergies</li>
<li>Expects to achieve cash flow breakeven in the third quarter of 2025 &nbsp;</li>
</ul>
MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) (the "Company") today announced preliminary fourth quarter and full year 2024 revenue and issued 2025 financial guidance.
Preliminary Fourth Quarter and Full Year 2024 Results
Neuronetics' preliminary unaudited fourth quarter and full year revenue 2024 was $22.1 and $74.5, respectively. These results reflect Neuronetics' standalone performance through December 10, 2024, and combined performance with Greenbrook TMS for the remainder of the year. In the quarter, the Company shipped 50 systems.

Neuronetics Announces Q4 Revenue Of $22.1M And FY24 Revenue Of $74.5M; Projects 12%-19% Revenue Growth And $22M In Synergies For 2025; Aims For Cash Flow Breakeven In Q3 2025

<h3>Gainers</h3>
<ul>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock rose 61.6% to $0.21 during Tuesday's pre-market session. The company's market cap stands at $2.5 million. As per the news, the Q3 earnings report came out today. </li>
<li>CERo Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares increased by 46.12% to $0.29. The market value of their outstanding shares is at $43.0 million. </li>
<li>Nevro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) shares increased by 28.75% to $6.85. The market value of their outstanding shares is at $255.3 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLDP#NASDAQ">CCLDP</a>) shares rose 28.17% to $15.97. </li>
<li>Taysha Gene Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSHA#NASDAQ">TSHA</a>) shares rose 27.56% to $2.08. The company's market cap stands at $426.1 million. </li>
<li>CareCloud (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCLD#NASDAQ">CCLD</a>) shares moved upwards by 22.6% to $3.2. The market value of their outstanding shares is at $51.8 million. As per the press release, Q3 earnings came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) stock decreased by 40.2% to $1.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $166.8 million. As per the press release, Q3 earnings came out today. </li>
<li>Neurogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) stock decreased by 31.36% to $49.1. The company's market cap stands at $728.0 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 27.28% to $0.8. The market value of their outstanding shares is at $24.2 million. The company's, Q3 earnings came out today. </li>
<li>Rockwell Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMTI#NASDAQ">RMTI</a>) shares decreased by 25.81% to $3.45. The market value of their outstanding shares is at $107.0 million. The company's, Q3 earnings came out today. </li>
<li>Syndax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDX#NASDAQ">SNDX</a>) stock fell 25.3% to $16.27. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares declined by 18.4% to $0.82. The market value of their outstanding shares is at $116.1 million. As per the press release, Q3 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CCLD

CCLDP

CERO

HRTX

LGMK

NGNE

NVRO

RMTI

SNDX

TSHA

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Neuronetics shares are trading lower after the company reported worse-than-expected Q3 financial result and cut its FY24 sales guidance. Also, the company issued Q4 sales guidance below estimates.

Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.23) by 91.3 percent. This is a 33.33 percent decrease over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $18.53 million which missed the analyst consensus estimate of $19.13 million by 3.14 percent. This is a 3.61 percent increase over sales of $17.88 million the same period last year.

Neuronetics Q3 EPS $(0.44) Misses $(0.23) Estimate, Sales $18.53M Miss $19.13M Estimate

Press Releases

Neuronetics Provides Business Update and Issues 2025 Guidance

Health Care

NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression

Neuronetics Announces Launch of Underwritten Public Offering of Common Stock

Neuronetics Announces Pricing of $18 Million Underwritten Public Offering of Common Stock

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

Neuronetics Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Neuronetics Reports Updated Fourth Quarter and Full Year 2024 Financial and Operating Results

Evernorth Health Services, a Cigna Company, Expands NeuroStar® TMS Coverage for Adolescents Struggling with Depression

Comments

Neuronetics

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO